Biome Australia Limited (ASX:BIO) Secures FaBA Co-Investment for IP Development
Investment Agreement
Biome Australia Limited (ASX:BIO) has signed a co-investment agreement with the Australian Food and Beverage Accelerator (FaBA) to fund the development of its BMB18 probiotic strain in collaboration with UQ, QUT, and UniSQ.
Funding Details
The partnership is supported by $50 million from the Australian Government Department of Education Trailblazer Program. Biome may contribute up to $550,000 over two years, with FaBA and its federal government research grant matching the investment.
Intellectual Property
Biome retains 100% ownership of the intellectual property related to Lactobacillius plantarum BMB18 and any arising from the project, royalty free.
Research and Development
The collaboration builds on Biome’s successful in vitro studies showing BMB18’s potential in modulating immune responses, reducing inflammation and oxidative stress, and maintaining intestinal barrier integrity, aligning with Biome’s Vision 27 clinical pipeline.
Motley Fool contributor Kiarra Jackson has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.